Astrazeneca Ab

Neomed Institute

Epigenetix, Inc.

Andrew Griffin

William Brown

Christopher Walpole

Shawn Donald Johnstone

Malken Bayrakdarian

Stephen Claridge

Jeffrey S Albert

Guillaume Jacquemot

Denis Labrecque

Paul Jones

Mehrnaz Pourashraf

Niklas Plobeck

Steven Sigmund Wesolowski

Scott Throner

Todd Andrew Brugel

Phil Edwards

James Arnold

Yevgeni Besidski

Inger Kers

Karin Skogholm

Thierry Groblewski

Dean Brown

Martin Nylöf

Daniel Pagé

Martin Nylof

Thomas Hudzik

Daniel Page

Marc-Andre Beaulieu

Carla Maciag

Gennady Smagin

Shawn Johnstone

This application relates to substituted benzimidazoles, compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted benzimidazoles and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.

Substituted benzimidazoles, their preparation and their use as pharmaceuticals

This application relates to N-substituted bicyclic lactams of formula (I), compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to the N-substituted bicyclic lactams of formula (I) and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers. 

N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals

This application relates to substituted [1,2,4]triazolo[4,3-a]pyridines of formula (I), compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted [1,2,4]triazolo[4,3-a]pyridines and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers. 

Substituted [1,2,4]triazolo[4,3-A]pyridines, their preparation and their use as pharmaceuticals

This application relates to aryl-substituted dihydroquinolinones of formula (I), compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to aryl-substituted dihydroquinolinones and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers. 

Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals

This application relates to substituted imidazopyridines, compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted imidazopyridines of Formula I and to their use as bromodomain inhibitors.  The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.

Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors

Disclosed herein is at least one cyclopropyl amide derivative, at least one pharmaceutical composition comprising at least one cyclopropyl amide derivative disclosed herein, and at least one method of using at least one cyclopropyl amide derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith.

Cyclopropyl amide derivatives

The present invention relates to new compounds or salts, solvates or solvated salts thereof, processes for their preparation and to new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in therapy.

Compounds

Compounds of general formula: as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain, depression and anxiety.

Diarylmethyl piperazine derivatives, preparations thereof and uses thereof

Compounds of general formula: wherein R, Rand Rare as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders

Compounds of general formula: wherein Rand Rare as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

4(Phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders

Growing community of inventors

Montreal, Canada

Andrew Griffin